FDA alert: counterfeit Ozempic pens found in US supply chain
Ozempic (counterfeit) · Announced 2023-12-21 · Last reviewed July 2026
On December 21, 2023 the FDA alerted patients, pharmacies, and wholesalers that counterfeit Ozempic (semaglutide) 1 mg pens had entered the US drug-supply chain outside authorized channels. The counterfeit products carry lot number NAR0074 with serial number 430834149057. FDA and Novo Nordisk seized thousands of units and advised that the pen needles in the counterfeit kits are themselves counterfeit, so their sterility cannot be assured. FDA reported a small number of adverse-event reports associated with the lot, none serious and consistent with known GI side effects of semaglutide. Wholesalers, pharmacies, and patients were told not to distribute, dispense, or use pens labeled with that lot/serial combination.
What's affected
- Ozempic 1 mg pens labeled lot NAR0074, serial 430834149057
- Distributed outside Novo Nordisk's authorized wholesale channels
- Authentic Novo Nordisk Ozempic from authorized distributors is unaffected
What patients should do
- Check the lot and serial number on your Ozempic pen against the FDA alert before use
- Buy Ozempic only from state-licensed pharmacies supplied through authorized distributors
- If you have a pen from the counterfeit lot, do not use it — return it to the dispensing pharmacy and notify FDA MedWatch
- Report any adverse events to your prescriber and FDA MedWatch